From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
STAT17h
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...